Zhang J, Cashm an J R. Quantitative analysis of FMO gene mRNA levels in hum an tissues[J]. Drug Metab Dispos, 2006, 34(1):19.
[2]
Mwenifumbo J C, Tyndale R F. Molecular genetics of nicotine metabolism[J]. Handb Exp Pharmacol, 2009(192):235.
[3]
Byrd G D, Chang K M, Greene J M, et al. Evidence for urinary excretion of glucuronide conjugates of nicotine, cotinine, and trans-30-hydroxycotinine in smokers[J]. Drug Metab Dispos, 1992, 20:192.
[4]
Aysun Türkano？lu ？z？elik,Birsen Can Demird？？en. Flavin containing monooxygenase 3 genetic polymorphisms Glu158Lys and Glu308Gly and their relation to ischemic stroke[J]. Gene, 2013, 521:116.
[5]
Shephard E A, Dolphin C T, Fox M F, et al. Localization of genes encoding three distinct flavin-containing monooxygenase to human chromosome 1q[J]. Genomics, 1993, 16: 85.
[6]
Dolphin C T, Riley J H, Smith R L, et al . Structural organization of the human flavin-containing monoxygenase 3 gene(FMO3),the favored candidate for fish-odor syndrome, determined diectly from genomic DNA[J]. Genomics, 1997, 46: 260.
[7]
Phillips I R, Shephard E A. Trimethylaminuria[M].Gene Rev, 2011.
[8]
Hernandez D, Addou S. Trimethylaminuria and a human FMO3 mutation database[J]. Hum Mutat, 2003, 22: 209.
[9]
Motika M S, Zhang J. Novel variants of the human flavin-containing monooxygenase 3 (FMO3) gene associated with trimethylaminuria[J]. Mol Genet Metab, 2009, 97(2): 128.
[10]
Rosalia D\'Angelo, Teresa Esposito. FMO3 allelic variants in Sicilian and Sardinian populations: trimethylaminuria and absence of fish-like body odor[J]. Gene, 2013, 515(2): 410.
Treacy E P, Akerman B R, Chow L M, et al. Mutations of the flavin-containing monooxygen ase gene (FMO3) cause trimethylaminuria,a defect in detoxication[J].Hum Mol Genet, 1998, 7(5) : 839.
Shubhada S, Shripad V B. Flavin-containing monooxygenase mediated metabolism of psychoactive drugs by human brain microsomes[J].Brain Res, 1995, 672:276.
[15]
Caron G, Gaillard P. Lipophilicity behavior of model and medicinal compounds containing a sulfide, sulfoxide, or sulfone moiety[J].Helv Chim Acta, 1997, 80:449.
[16]
Koukouritaki S B, Poch M T, Henderson M C, et al. Identification and functional analysis of common human flavin-containing monooxygenase 3 genetic variants[J]. Pharmacol, 2007,320:266.
[17]
Lattard V, Zhang J. Two new polymorphisms of the FMO3 gene in Caucasian and African-American populations: comparative genetic and functional studies[J]. Drug Metab Dispos, 2003, 31(7):854.
[18]
Cashman J R. The role of flavin-containing monooxygenases in drug metabolism and developm ent[J]. Curr Opin Drug Discov Dev, 2003, 6(4): 486.
[19]
Cashman J R. Some distinctions between flavin-containing and cytochrome P450 mon ooxygenases[J]. Biochem Biophys Res Commun, 2005, 338(1): 599.
[20]
Henderson M C, Siddens L K. Metabolism of the anti-tuberculosis drug ethionamide by mouse and human FMO1, FMO2 and FMO3 and mouse and human lung microsomes[J]. Toxicol Appl Pharmacol, 2008, 233: 420.
Cruciani G, Valeri A. Flavin monooxygenase metabolism: why medicinal chemists should matter[J]. J Med Chem, 2014,57:6183.
[23]
Krueger S K, Williams D E. Mammalain flavin-containing monooxygenases structrue/function, genetic polymorphisms and role in drug metabolism[J]. Phamacol Ther, 2005, 106(3): 357.
[24]
Cashman J R. The implications of polymorphisms in mammalian flavin-containing monooxygenases in drug discovery and development[J]. Drug Discov Today, 2004,9(13): 574.
Hernandez D, Janmohamed A. Organization and evolution of the flavin-containing monooxygenase genes of human and mouse: identification of novel gene and pseudogene cluster[J]. Pharmacogenetics, 2004(14):117.
[27]
Janmohamed A, Hernandez D, Phillips I R, et al. Cell-, tissue-, sex- and developmental stage-specific expression of mouse flavin-containing monooxygenases(FMOs)[J]. Biochem Pharmacol, 2004, 68(1):73.
[28]
Koukouritaki S B, Simpson P, Yeung C K, et al. Human hepatic flavin-containing monooxygenases 1(FMO1) and 3 (FMO3) evelopmental expression[J]. Pediatr Res, 2002, 51(2):236.
[29]
Cherrington N J, Cao Y, Cherrington J W, et al. Physiological factors affecting protein expression of flavin-containing monooxygenases 1, 3 and 5[J]. Xenobiotica, 1998, 28(7):673.
[30]
Yamazaki H, Shimizu M. Survey of variants of human flavin-containing monooxygenase 3(FMO3) and their drug oxidation activities[J]. Biochem Pharm, 2013, 85: 1588.
[31]
Caron G, Ermondi G Testa.Structure property relations in the basicity and lipophilicity of arylalkylamine oxides[J]. Helv Chim Acta, 1999, 82: 1630.
[32]
Zschocke J,Mayatepek E. Biochemical and molecular studies in mild flavin monoooxygenase 3 deficiency[J]. J Inherit Metab Dis, 2000, 23(4): 378.
[33]
Mayatepek E,Flock B. Benzydamine metabolism in vivo is impaired in patients with deficiency of flavin-containing monooxygenase 3[J]. Pharmacogenetics, 2004, 14(11): 775.
[34]
Cashman J R. Stereoselectivity in S- and N-oxygenation by the mammalian flavin-containing and cytochrome P-450 monooxygenases [J]. Drug Metab Rev, 1998, 30(4) : 675.
